MarketCap
Facebook
X
Telegram
Apellis Pharmaceuticals Income Statement 2025-2011 | APLS
Brief overview of financial performance at Apellis Pharmaceuticals
The comparison covers a five-year financial horizon. According to figures from Apellis Pharmaceuticals, revenue changed from $251 million to $1 billion over five years. The total change was +300.5%, with a CAGR of approximately 32%. This pace points to rapid expansion of the business.
EBITDA changed from −$213 million to $57 million (+126.7%). Changes in revenue did not translate into comparable EBITDA performance. At the operating-margin level, the figure shifted from −85% to 5.7%. The business generated more EBITDA from each unit of revenue.
Comparing the endpoints shows a move from −$345 million to $22.4 million. The trajectory reversed from a loss to positive earnings.
The market value of the business moved from 3.3 billion dollars to 2.8 billion dollars, or −16.6%. Capitalization grew more slowly than the underlying results.
Conclusion
The results point to consistent and sustainable progress. Key strengths include a stronger final result, a larger revenue base and positive operating leverage. The next reporting periods will show whether revenue, margins, and final profitability can strengthen.
Annual Income Statement Apellis Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
2.77 B | 3.08 B | 8.28 B | 6.45 B | 3.4 B | 3.33 B | 2.58 B | 738 M | 253 M | - | - | - | - | - | - |
Shares |
126 M | 124 M | 119 M | 106 M | 84.4 M | 75.2 M | 62.2 M | 54.4 M | 13.9 M | - | - | - | - | - | - |
Historical Prices |
22 | 24.9 | 69.7 | 60.8 | 40.3 | 44.3 | 41.1 | 14 | 16.6 | - | - | - | - | - | - |
Net Income |
22.4 M | -198 M | -529 M | -652 M | -746 M | -345 M | -305 M | -128 M | -51 M | -27.1 M | -46.5 M | -10.8 M | -3.96 M | - | - |
Revenue |
1 B | 781 M | 397 M | 75.4 M | 66.6 M | 251 M | - | - | - | - | - | - | - | - | - |
Operating Income |
55.4 M | -165 M | -517 M | -595 M | -536 M | -214 M | -288 M | -128 M | -50.8 M | -27.3 M | -46.6 M | - | - | - | - |
Interest Expense |
-133 K | -2.17 M | -727 K | -288 K | 1.36 M | -501 K | -175 K | -25 K | -142 K | 22.4 K | - | - | - | - | - |
EBITDA |
57 M | -163 M | -515 M | -593 M | -535 M | -213 M | -288 M | -125 M | -50.8 M | -27.3 M | 6.4 M | -11.3 M | -4.02 M | - | - |
Operating Expenses |
948 M | 946 M | 914 M | 670 M | 603 M | 464 M | 288 M | 128 M | 50.8 M | - | - | - | - | - | - |
General and Administrative Expenses |
550 M | 501 M | 501 M | 277 M | 177 M | 139 M | 67 M | 22.6 M | 10.5 M | 4.3 M | 6.36 M | 2.91 M | 1.71 M | - | - |
All numbers in USD currency
Quarterly Income Statement Apellis Pharmaceuticals
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
128 M | 126 M | 126 M | 125 M | 124 M | 124 M | 124 M | 123 M | 120 M | 120 M | 119 M | 114 K | 111 M | 109 K | 107 K | 98.1 K | 97.5 M | 85.7 K | 80.7 K | 79.2 M | 76.1 M | 75.6 M | 75.6 M | 73.7 M | 63.9 M | 63.8 K | 63.3 K | 57.9 K | 56.3 M | 56.2 M | 54.7 M | 50.4 M | 50.3 M | 8.44 M | 8.43 M | 8.43 M | 8.43 M | 8.43 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Net Income |
18.7 M | 216 M | -42.2 M | -92.2 M | - | -57.4 M | -37.7 M | -66.4 M | - | -140 M | -122 M | -178 M | - | -191 M | -156 M | -139 M | - | -196 M | -219 M | -184 M | 78.3 M | -136 M | -119 M | -169 M | -113 M | -69.8 M | -71.1 M | -50.6 M | -36.5 M | -36 M | -33.3 M | -21.7 M | -18.3 M | -11.6 M | -12.1 M | -9.05 M | -6.62 M | -7.21 M | -7.29 M | -6 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Revenue |
268 M | 459 M | 178 M | 167 M | - | 197 M | 200 M | 172 M | - | 110 M | 95 M | 44.8 M | - | 22.1 M | 16.3 M | 14.4 M | - | 5.65 M | 623 K | - | - | 646 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Income |
26.5 M | 223 M | -33.3 M | -83.3 M | - | -47.3 M | -29.4 M | -62.1 M | - | -137 M | -120 M | -175 M | - | -153 M | -149 M | -129 M | - | -128 M | -194 M | -125 M | 130 M | -130 M | -116 M | -98.8 M | -106 M | -69.9 M | -63.5 M | -48.7 M | -37.2 M | -35.8 M | -33.5 M | -21.4 M | -18 M | -11.6 M | -12.1 M | -9.05 M | -6.25 M | -7.23 M | -7.57 M | -6.23 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Interest Expense |
88 K | 37 K | 146 K | -165 K | - | 70 K | 24 K | -499 K | - | -603 K | -63 K | -277 K | - | 99 K | 149 K | -289 K | - | -117 K | -61 K | 1.54 M | - | -16 K | 5 K | 14 K | - | -61 K | 228 K | -253 K | - | -22.2 K | -32.9 K | -31.5 K | - | -801 | 397 | - | - | 23.6 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA |
26.8 M | 224 M | - | -82.9 M | - | - | - | -61.6 M | - | - | - | -175 M | - | -152 M | -148 M | -129 M | - | -127 M | -194 M | -124 M | 130 M | -129 M | -115 M | -98.7 M | -106 M | -69.8 M | -63.4 M | -48.6 M | -37.2 M | -35.8 M | -33.5 M | -21.4 M | -18 M | -11.6 M | -12.1 M | -9.05 M | -6.25 M | -7.23 M | -7.57 M | -6.23 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Expenses |
242 M | 235 M | 212 M | 250 M | - | 244 M | 229 M | 234 M | - | 247 M | 215 M | 220 M | - | 175 M | 165 M | 143 M | - | 134 M | 195 M | 125 M | - | 130 M | 116 M | - | - | 69.9 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
General and Administrative Expenses |
124 M | 143 M | 131 M | 129 M | - | 122 M | 128 M | 130 M | - | 146 M | 111 M | 102 M | - | 78.4 M | 63.2 M | 51.2 M | - | 45.8 M | 49 M | 40.6 M | - | 37 M | 28.4 M | 29.5 M | - | 18.6 M | 12.8 M | 8.17 M | - | 6.27 M | 5.95 M | 4.04 M | - | 2.07 M | 1.71 M | 1.82 M | - | 1 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
The income statement is one of the three key financial reports of a company Apellis Pharmaceuticals (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
Russia
USA
Canada
Germany
China
Israel
France
Britain
Belgium
